Skeletal in Biological Technology

Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia

... be shown to significantly improve the devastating skeletal manifestations of hypophosphatasia and may ... perinatal or infantile forms, with profound skeletal hypomineralization and respiratory compromise ... significantly improved survival, prevented the skeletal and dental manifestations of the disease and ...

Algeta Appoints Andrew Kay as President and Chief Executive Officer

... in 2008 as a novel treatment for patients with skeletal metastases from hormone refractory prostate ... alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as ... Alpharadin is a unique targeted treatment for skeletal metastases in cancer patients and is based on ...

Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice

... replacement therapy with ENB-0040 may help repair skeletal damage caused by hypophosphatasia, as well as ... to significantly improve survival and prevent skeletal and dental manifestations of the disease. ... severe perinatal or infantile form, with profound skeletal hypomineralization and respiratory compromise ...

Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June

... Muscular skeletal Managed Care Organization Takes Prominent ... as the imminent leader in innovative muscular skeletal healthcare solutions," said Paul Candino, ... leader in delivering patient-focused muscular skeletal solutions that result in optimal clinical ...

Hologic Announces First Quarter Fiscal 2008 Operating Results

... Care), Diagnostics, GYN Surgical and skeletal Health. The Diagnostics and GYN Surgical ... mini C-arm and MRI products are included in skeletal Health. First quarter financial overview by ... $.7 million of stock-based compensation. -- skeletal Health revenues decreased to $24.3 million for ...

Muscular protein bond -- strongest yet found in nature

... as medical research and nanotechnology. The real strength of any skeletal muscle doesn't start with exercise; it comes ultimately from nanoscale ... the macroscale function of the organism contraction and relaxation of skeletal muscles. Advanced biological and physical techniques gave the ...

Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009

... of Cisatracurium Besylate is now China's top-selling pre-surgical skeletal muscle relaxant. Sales of Clindamycin, an antibiotic, increased by ... its application for approval of Rocuronium bromide, a next generation skeletal muscle relaxant that is also the first that can be stored at room ...

VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo

... in oncology as well as inflammatory, pulmonary, cardiovascular and skeletal disease. The late-breaking poster "In vivo imaging of treatment ... in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical ...

Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier

... to Act as Agent to Find Partner to Co-Develop Company's Chinese Patented skeletal Muscle Relaxant for North American Markets LAS VEGAS, April 3 ... new version of Cisatracurim besylate, a non-depolarizing pre-surgical skeletal muscle relaxant, for use in North America. Kingchem will also source ...

Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation

... "Long-term durability, tissue regeneration and neo-organ growth during skeletal maturation with a Neo-Bladder Augmentation Construct" was co-authored by ... continued to adapt in size and function with overall animal growth, or skeletal maturation. "The results of this study are very encouraging for our ...

Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights

... of each of our compounds. With G4544, an internally developed compound for skeletal diseases, we have the opportunity to submit a NDA for a product via a ... Agency (EMEA) for Scientific Advice. G4544: A New Oral Drug for skeletal Diseases G4544 is the Company's proprietary small molecule that is ...

800-Year-Old Mummies Aid Current Cold Cases:

... University of New Haven have developed a new method for preparing certain skeletal remains for DNA extraction thanks to some 800-year-old mummies from ... Gobi research continued, the team tried unsuccessfully to extract DNA from skeletal remains that had been buried in the U.S. Then, Coyle remembered how ...

iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming

... at Harvard University , and principal faculty member of the Harvard Stem Cell Institute. Dr. Wagers is a leading expert in adult stem cells of skeletal muscle and bone marrow. About iPierian iPierian is a South San Francisco-based biopharmaceutical company focused on the ...

2009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process

... authorization for Immunotec to conduct a clinical trial of IMMUNOCAL(R) in elderly persons. Aging is typically associated with a decrease in skeletal muscle mass and muscle function, which contributes decisively to disability in old age and to a loss of quality of life. Resistance training exercise ...

VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent

... used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and ...

Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August

... denosumab's ability to reduce the incidence of fractures, and all six studies showed denosumab's ability to increase bone mineral density at all skeletal sites measured. In the two pivotal studies with fracture endpoints, the incidence and types of adverse events with denosumab were similar to placebo. ...

Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate

... Board: SNBP) is pleased to announce that it has applied for two Chinese patents for its flagship product, Cisatracurim besylate, a pre-surgical skeletal muscle relaxant. The Company has applied to China's State Intellectual Property Office (SIPO) for a Chinese patent for Atracurium's ...

ETEX Corporation Announces FDA Clearance of Small Size Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty

... bone over time. Beta-bsm(TM) Injectable Paste and Gamma-bsm(TM) Moldable Putty are intended for use in filling bone voids or defects of the skeletal system (including extremities, pelvis, and spine) that are not intrinsic to the stability of the bone structure. ETEX's rapidly expanding product ...

Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009

... share. Increase in sales volume and the improvement in gross profit percentage are both due to growth in sales of Cisatracurium Besylate, a skeletal muscle relaxant. Sales of this product increased to US $2,511,752 in the nine months ended February 28, 2009, from US $765,615 in the nine months ...

Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009

... share. Increase in sales volume and the improvement in gross profit percentage are both due to growth in sales of Cisatracurium Besylate, a skeletal muscle relaxant. Sales of this product increased to US $2,511,752 in the nine months ended February 28, 2009, from US $765,615 in the nine months ...

Life sticks: UC San Diego bioengineer's sticky insights published in journal Science

... with Rick Lieber, Ph.D., Professor and Vice Chair of UC San Diego's Department of Orthopedic Surgery and Director of the National Center for skeletal Muscle Rehabilitation Research, based at UC San Diego. Lieber is also Senior Research Career Scientist at the Veterans Affairs San Diego Health ...

BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA

... of N-acetylgalactosamine 6-sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance. Malformation of the thorax as well as macrophage dysfunction ...

Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008

... Increase in sales volume and the improvement in gross profit percentage are both due to growth in sales of Cisatracurium Besylate., a skeletal muscle relaxant. Sales of this product increased to $1,756,798 in the six months ended November 30, 2008 from $505,331 in the six months ended ...

Hologic, Inc. to Host Investor Reception at the RSNA Trade Show

... dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage ...

Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.

... utilize these technologies along with others being developed internally to create cost effective growth factor containing bone grafts for mammalian skeletal regeneration. ...

HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City

... Screening -- A bone densitometer provides a Bone Mineral Density (BMD) measurement, expressed as a "T Score," as well as fracture risk and skeletal strength. Osteoporosis is a disease in which bones become fragile and more likely to break. If undetected and left untreated, osteoporosis will ...

Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules

... Extended-Release Capsules). In the Notice Letter, Mylan alleges that the U.S. Patent Number 7,387,793, entitled "Modified Release Dosage Forms of skeletal Muscle Relaxants," issued to Eurand is invalid, unenforceable and/or will not be infringed by Mylan's manufacture, use or sale of the product ...

Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures

... Of 60,112 patients, 11,276 reported an osteoporosis diagnosis. Data on the occurrence of fracture since the age of 45 years was collected for 10 skeletal sites (spine, ankle, arm, collarbone, hip, pelvis, rib, wrist, and upper and lower leg). Fracture history was correlated to a patient's ...

VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent

... are widely used by leading research institutions and pharmaceutical companies in disease areas including oncology, inflammation, cardiovascular, skeletal and pulmonary diseases. The Company also works with pharmaceutical and clinical partners to design and develop ranges of tailored molecular imaging ...

ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)

... in the 510k submission which received FDA clearance on April 28, 2008. EquivaBone(TM) is intended for use in filling bone voids or defects of the skeletal system (including extremities, pelvis, and spine) that are not intrinsic to the stability of the bone structure. ETEX will market EquivaBone(TM) ...

Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights

... to improve convenience, safety, and activity for patients who are currently receiving conventional taxanes. G4544: A New Oral Drug for skeletal Diseases G4544 is the Company's proprietary small molecule that is intended to treat diseases associated with accelerated bone loss. G4544 contains ...

Worldwide Center for Adult Stem Cell Education LLC Changes Name to 'The Repair Stem Cell Institute LLC'

... quality of life of the patient. "Repair stem cells are made to repair, and their derivation, characterization and utility can be found in skeletal muscle, dental pulp, prostate, kidney, the eye and many other tissues, and scientists are just scratching the surface about their many applications ...

BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use

... cell lines (called "progenitor" cell lines) possess the potential to expand and become specific types of tissues and cells such as heart, skeletal muscle, bone, retinal, nerve, pancreas and others – all necessary to study various human diseases where regenerative medicine shows great ...

BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even

... exciting dividends for the company. Canada -- As many of our investors know, BioElectronics received full Health Canada certification for muscular skeletal complaints, which allows us to market our products over the counter throughout Canada. We feel this is a very exciting development for BioElectronics ...

Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty

... LA demonstrated continued profound hormone suppression with no escapes (breakthrough of hormones) and led to continued decreases in rates of growth, skeletal maturation and body mass index at 24 months compared to 12 months. "This study confirms that SUPPRELIN LA maintains remarkable suppression of peak ...

FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA

... of injection site pain. Important Safety Information In clinical trials, the most common adverse events occurring in patients were hot flushes, skeletal pain, impotence and headache. As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels and may initiate or ...

Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite

... Biocomposite. Adapting the Company's proprietary Plexur(R) Technology, Plexur M(TM) is intended for use in filling bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure. During the healing process, Plexur M(TM) is remodeled and replaced by host ....

Schering-Plough Announces Sugammadex New Drug Application Filed in Japan

... reverse shallow and profound depths of rocuronium-induced neuromuscular blockade (NMB), thereby enabling control of the onset and offset of skeletal muscle relaxation through the use of both drugs. Sugammadex also has demonstrated the ability to reverse the effects of NMB induced by vecuronium ...

Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA

... reverse shallow and profound depths of rocuronium-induced neuromuscular blockade (NMB), thereby enabling control of the onset and offset of skeletal muscle relaxation through the use of both drugs. Sugammadex also has demonstrated the ability to reverse the effects of NMB induced by vecuronium ...

Amarin Signs Agreement to Acquire Ester Neurosciences

... primary disorder of neuromuscular transmission. It is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. About 10% of MG patients develop a life threatening weakness of the respiratory muscles needed for breathing, a ...